The neurodegenerative disease therapy developer has set a $100m placeholder target for an offering following $140m in funding from investors including Amgen and Pivotal BioVentures.

US-based neurodegenerative disease drug developer Vigil Neuroscience has filed for an initial public offering on the Nasdaq Global Market, marking a potential exit for pharmaceutical firm Amgen.

Founded in 2020, Vigil Neuroscience uses microglia, the main active immune cells in the central nervous system, as the basis for drugs intended to target and treat neurodegenerative diseases. It has set a $100m placeholder target for the offering.

Proceeds from the IPO will go toward the development of the company’s line of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn